APO Research
Talk to an analyst

APO RESEARCH · REPORT

Neutropenia Biologic Drug Treatment

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Neutropenia Biologic Drug Treatment Market Analysis and Forecast 2026-2032

31 December 2025196 pages

Choose your research edition.

Industry ResearchNeutropenia Biologic Drug Treatment Industry Research Report 2026124 pages · $2,950 USDIndustry Growth & TrendsGlobal Neutropenia Biologic Drug Treatment Industry Growth and Trends Forecast to 2032101 pages · $3,450 USDMarket StructureGlobal Neutropenia Biologic Drug Treatment Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Neutropenia Biologic Drug Treatment Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal Neutropenia Biologic Drug Treatment Market Analysis and Forecast 2026-2032196 pages · $4,950 USD

Market perspective

The global Neutropenia Biologic Drug Treatment market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Neutropenia Biologic Drug Treatment is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Neutropenia Biologic Drug Treatment is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Neutropenia Biologic Drug Treatment is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Neutropenia Biologic Drug Treatment is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Neutropenia Biologic Drug Treatment include Kyowa Kirin, Teva Pharmaceutical Industries Ltd., Sanofi, Novartis, Pfizer, Baxter International, Amgen, Partner Therapeutics and Myelo Therapeutics GmbH, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Neutropenia Biologic Drug Treatment, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Neutropenia Biologic Drug Treatment, also provides the revenue of main regions and countries. Of the upcoming market potential for Neutropenia Biologic Drug Treatment, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Neutropenia Biologic Drug Treatment revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Neutropenia Biologic Drug Treatment market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Neutropenia Biologic Drug Treatment revenue, projected growth trends, production technology, application and end-user industry.

Neutropenia Biologic Drug Treatment Segment by Company

Kyowa Kirin

Teva Pharmaceutical Industries Ltd.

Sanofi

Novartis

Pfizer

Baxter International

Amgen

Partner Therapeutics

Myelo Therapeutics GmbH

Enzychem Lifesciences Corporation

Dong-A ST Co.,Ltd.

CVS Health

Cellerant Therapeutics

Neutropenia Biologic Drug Treatment Segment by Type

Filgrastim

Lenograstim

Pegfilgrastim

Sargramostim

Lipegfilgrastim

Neutropenia Biologic Drug Treatment Segment by Application

Hospital Pharmacies

Online Pharmacies

Retail Pharmacies

Neutropenia Biologic Drug Treatment Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Neutropenia Biologic Drug Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Neutropenia Biologic Drug Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Neutropenia Biologic Drug Treatment.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Neutropenia Biologic Drug Treatment in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Neutropenia Biologic Drug Treatment company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Neutropenia Biologic Drug Treatment revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Neutropenia Biologic Drug Treatment Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Filgrastim Major Player Table 3. Lenograstim Major Player Table 4. Pegfilgrastim Major Player Table 5. Sargramostim Major Player Table 6. Lipegfilgrastim Major Player Table 7. Global Neutropenia Biologic Drug Treatment Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 8. Hospital Pharmacies Major Player Table 9. Online Pharmacies Major Player Table 10. Retail Pharmacies Major Player Table 11. Neutropenia Biologic Drug Treatment Industry Trends Table 12. Neutropenia Biologic Drug Treatment Industry Drivers Table 13. Neutropenia Biologic Drug Treatment Industry Opportunities and Challenges Table 14. Neutropenia Biologic Drug Treatment Industry Restraints Table 15. Global Neutropenia Biologic Drug Treatment Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 16. Global Neutropenia Biologic Drug Treatment Market Size by Region (2021-2026) & (US$ Million) Table 17. Global Neutropenia Biologic Drug Treatment Market Share by Region (2021-2026) Table 18. Global Neutropenia Biologic Drug Treatment Market Size by Region (2027-2032) & (US$ Million) Table 19. Global Neutropenia Biologic Drug Treatment Market Share by Region (2027-2032) Table 20. Global Neutropenia Biologic Drug Treatment Revenue by Players (US$ Million) & (2021-2026) Table 21. Global Neutropenia Biologic Drug Treatment Revenue Market Share by Players (2021-2026) Table 22. Global Neutropenia Biologic Drug Treatment Key Players Ranking, 2024 VS 2025 VS 2026 Table 23. Global Neutropenia Biologic Drug Treatment Key Players Headquarters & Area Served Table 24. Global Neutropenia Biologic Drug Treatment Players, Product Type & Application Table 25. Global Neutropenia Biologic Drug Treatment Players Establishment Date Table 26. Global Players Market Concentration Ratio (CR5 and HHI) Table 27. Global Neutropenia Biologic Drug Treatment by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 28. Global Neutropenia Biologic Drug Treatment Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global Neutropenia Biologic Drug Treatment Revenue by Type (2021-2026) & (US$ Million) Table 30. Global Neutropenia Biologic Drug Treatment Revenue by Type (2027-2032) & (US$ Million) Table 31. Global Neutropenia Biologic Drug Treatment Revenue Market Share by Type (2021-2026) Table 32. Global Neutropenia Biologic Drug Treatment Revenue Market Share by Type (2027-2032) Table 33. Global Neutropenia Biologic Drug Treatment Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global Neutropenia Biologic Drug Treatment Revenue by Application (2021-2026) & (US$ Million) Table 35. Global Neutropenia Biologic Drug Treatment Revenue by Application (2027-2032) & (US$ Million) Table 36. Global Neutropenia Biologic Drug Treatment Revenue Market Share by Application (2021-2026) Table 37. Global Neutropenia Biologic Drug Treatment Revenue Market Share by Application (2027-2032) Table 38. Kyowa Kirin Company Information Table 39. Kyowa Kirin Business Overview Table 40. Kyowa Kirin Neutropenia Biologic Drug Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 41. Kyowa Kirin Neutropenia Biologic Drug Treatment Product Portfolio Table 42. Kyowa Kirin Recent Development Table 43. Teva Pharmaceutical Industries Ltd. Company Information Table 44. Teva Pharmaceutical Industries Ltd. Business Overview Table 45. Teva Pharmaceutical Industries Ltd. Neutropenia Biologic Drug Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 46. Teva Pharmaceutical Industries Ltd. Neutropenia Biologic Drug Treatment Product Portfolio Table 47. Teva Pharmaceutical Industries Ltd. Recent Development Table 48. Sanofi Company Information Table 49. Sanofi Business Overview Table 50. Sanofi Neutropenia Biologic Drug Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 51. Sanofi Neutropenia Biologic Drug Treatment Product Portfolio Table 52. Sanofi Recent Development Table 53. Novartis Company Information Table 54. Novartis Business Overview Table 55. Novartis Neutropenia Biologic Drug Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 56. Novartis Neutropenia Biologic Drug Treatment Product Portfolio Table 57. Novartis Recent Development Table 58. Pfizer Company Information Table 59. Pfizer Business Overview Table 60. Pfizer Neutropenia Biologic Drug Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 61. Pfizer Neutropenia Biologic Drug Treatment Product Portfolio Table 62. Pfizer Recent Development Table 63. Baxter International Company Information Table 64. Baxter International Business Overview Table 65. Baxter International Neutropenia Biologic Drug Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 66. Baxter International Neutropenia Biologic Drug Treatment Product Portfolio Table 67. Baxter International Recent Development Table 68. Amgen Company Information Table 69. Amgen Business Overview Table 70. Amgen Neutropenia Biologic Drug Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 71. Amgen Neutropenia Biologic Drug Treatment Product Portfolio Table 72. Amgen Recent Development Table 73. Partner Therapeutics Company Information Table 74. Partner Therapeutics Business Overview Table 75. Partner Therapeutics Neutropenia Biologic Drug Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 76. Partner Therapeutics Neutropenia Biologic Drug Treatment Product Portfolio Table 77. Partner Therapeutics Recent Development Table 78. Myelo Therapeutics GmbH Company Information Table 79. Myelo Therapeutics GmbH Business Overview Table 80. Myelo Therapeutics GmbH Neutropenia Biologic Drug Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 81. Myelo Therapeutics GmbH Neutropenia Biologic Drug Treatment Product Portfolio Table 82. Myelo Therapeutics GmbH Recent Development Table 83. Enzychem Lifesciences Corporation Company Information Table 84. Enzychem Lifesciences Corporation Business Overview Table 85. Enzychem Lifesciences Corporation Neutropenia Biologic Drug Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 86. Enzychem Lifesciences Corporation Neutropenia Biologic Drug Treatment Product Portfolio Table 87. Enzychem Lifesciences Corporation Recent Development Table 88. Dong-A ST Co.,Ltd. Company Information Table 89. Dong-A ST Co.,Ltd. Business Overview Table 90. Dong-A ST Co.,Ltd. Neutropenia Biologic Drug Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. Dong-A ST Co.,Ltd. Neutropenia Biologic Drug Treatment Product Portfolio Table 92. Dong-A ST Co.,Ltd. Recent Development Table 93. CVS Health Company Information Table 94. CVS Health Business Overview Table 95. CVS Health Neutropenia Biologic Drug Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 96. CVS Health Neutropenia Biologic Drug Treatment Product Portfolio Table 97. CVS Health Recent Development Table 98. Cellerant Therapeutics Company Information Table 99. Cellerant Therapeutics Business Overview Table 100. Cellerant Therapeutics Neutropenia Biologic Drug Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 101. Cellerant Therapeutics Neutropenia Biologic Drug Treatment Product Portfolio Table 102. Cellerant Therapeutics Recent Development Table 103. North America Neutropenia Biologic Drug Treatment Revenue by Type (2021-2026) & (US$ Million) Table 104. North America Neutropenia Biologic Drug Treatment Revenue by Type (2027-2032) & (US$ Million) Table 105. North America Neutropenia Biologic Drug Treatment Revenue by Application (2021-2026) & (US$ Million) Table 106. North America Neutropenia Biologic Drug Treatment Revenue by Application (2027-2032) & (US$ Million) Table 107. North America Neutropenia Biologic Drug Treatment Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 108. North America Neutropenia Biologic Drug Treatment Revenue by Country (2021-2026) & (US$ Million) Table 109. North America Neutropenia Biologic Drug Treatment Revenue by Country (US$ Million) & (2027-2032) Table 110. Europe Neutropenia Biologic Drug Treatment Revenue by Type (2021-2026) & (US$ Million) Table 111. Europe Neutropenia Biologic Drug Treatment Revenue by Type (2027-2032) & (US$ Million) Table 112. Europe Neutropenia Biologic Drug Treatment Revenue by Application (2021-2026) & (US$ Million) Table 113. Europe Neutropenia Biologic Drug Treatment Revenue by Application (2027-2032) & (US$ Million) Table 114. Europe Neutropenia Biologic Drug Treatment Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 115. Europe Neutropenia Biologic Drug Treatment Revenue by Country (2021-2026) & (US$ Million) Table 116. Europe Neutropenia Biologic Drug Treatment Revenue by Country (US$ Million) & (2027-2032) Table 117. China Neutropenia Biologic Drug Treatment Revenue by Type (2021-2026) & (US$ Million) Table 118. China Neutropenia Biologic Drug Treatment Revenue by Type (2027-2032) & (US$ Million) Table 119. China Neutropenia Biologic Drug Treatment Revenue by Application (2021-2026) & (US$ Million) Table 120. China Neutropenia Biologic Drug Treatment Revenue by Application (2027-2032) & (US$ Million) Table 121. Asia Neutropenia Biologic Drug Treatment Revenue by Type (2021-2026) & (US$ Million) Table 122. Asia Neutropenia Biologic Drug Treatment Revenue by Type (2027-2032) & (US$ Million) Table 123. Asia Neutropenia Biologic Drug Treatment Revenue by Application (2021-2026) & (US$ Million) Table 124. Asia Neutropenia Biologic Drug Treatment Revenue by Application (2027-2032) & (US$ Million) Table 125. Asia Neutropenia Biologic Drug Treatment Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 126. Asia Neutropenia Biologic Drug Treatment Revenue by Region (US$ Million) & (2021-2026) Table 127. Asia Neutropenia Biologic Drug Treatment Revenue by Region (US$ Million) & (2027-2032) Table 128. SAMEA Neutropenia Biologic Drug Treatment Revenue by Type (2021-2026) & (US$ Million) Table 129. SAMEA Neutropenia Biologic Drug Treatment Revenue by Type (2027-2032) & (US$ Million) Table 130. SAMEA Neutropenia Biologic Drug Treatment Revenue by Application (2021-2026) & (US$ Million) Table 131. SAMEA Neutropenia Biologic Drug Treatment Revenue by Application (2027-2032) & (US$ Million) Table 132. SAMEA Neutropenia Biologic Drug Treatment Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 133. SAMEA Neutropenia Biologic Drug Treatment Revenue by Country (2021-2026) & (US$ Million) Table 134. SAMEA Neutropenia Biologic Drug Treatment Revenue by Country (US$ Million) & (2027-2032) Table 135. Research Programs/Design for This Report Table 136. Authors List of This Report Table 137. Secondary Sources Table 138. Primary Sources List of Figures Figure 1. Neutropenia Biologic Drug Treatment Image Figure 2. Global Neutropenia Biologic Drug Treatment Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Neutropenia Biologic Drug Treatment Market Size Share 2021 VS 2025 VS 2032 Figure 4. Filgrastim Image Figure 5. Lenograstim Image Figure 6. Pegfilgrastim Image Figure 7. Sargramostim Image Figure 8. Lipegfilgrastim Image Figure 9. Global Neutropenia Biologic Drug Treatment Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 10. Global Neutropenia Biologic Drug Treatment Market Size Share 2021 VS 2025 VS 2032 Figure 11. Hospital Pharmacies Image Figure 12. Online Pharmacies Image Figure 13. Retail Pharmacies Image Figure 14. Global Neutropenia Biologic Drug Treatment Market Size (US$ Million) & (2021-2032) Figure 15. Global Neutropenia Biologic Drug Treatment Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 16. Global Neutropenia Biologic Drug Treatment Market Share by Region: 2021 VS 2025 VS 2032 Figure 17. Global Neutropenia Biologic Drug Treatment Players Revenue Share Top 10 and Top 5 in 2025 Figure 18. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 19. Global Neutropenia Biologic Drug Treatment Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Neutropenia Biologic Drug Treatment Revenue Market Share 2021 VS 2025 VS 2032 Figure 21. Global Neutropenia Biologic Drug Treatment Revenue Market Share by Type (2021-2032) Figure 22. Global Neutropenia Biologic Drug Treatment Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global Neutropenia Biologic Drug Treatment Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 24. Global Neutropenia Biologic Drug Treatment Revenue Market Share by Application (2021-2032) Figure 25. North America Neutropenia Biologic Drug Treatment Revenue YoY Growth (2021-2032) & (US$ Million) Figure 26. North America Neutropenia Biologic Drug Treatment Revenue Share by Type (2021-2032) Figure 27. North America Neutropenia Biologic Drug Treatment Revenue Share by Application (2021-2032) Figure 28. North America Neutropenia Biologic Drug Treatment Revenue Share by Country (2021-2032) Figure 29. United States Neutropenia Biologic Drug Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Canada Neutropenia Biologic Drug Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 31. Mexico Neutropenia Biologic Drug Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 32. Europe Neutropenia Biologic Drug Treatment Revenue YoY Growth (2021-2032) & (US$ Million) Figure 33. Europe Neutropenia Biologic Drug Treatment Revenue Share by Type (2021-2032) Figure 34. Europe Neutropenia Biologic Drug Treatment Revenue Share by Application (2021-2032) Figure 35. Europe Neutropenia Biologic Drug Treatment Revenue Share by Country (2021-2032) Figure 36. Germany Neutropenia Biologic Drug Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. France Neutropenia Biologic Drug Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. U.K. Neutropenia Biologic Drug Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Italy Neutropenia Biologic Drug Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Spain Neutropenia Biologic Drug Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Russia Neutropenia Biologic Drug Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Netherlands Neutropenia Biologic Drug Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. Nordic Countries Neutropenia Biologic Drug Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 44. China Neutropenia Biologic Drug Treatment Revenue YoY Growth (2021-2032) & (US$ Million) Figure 45. China Neutropenia Biologic Drug Treatment Revenue Share by Type (2021-2032) Figure 46. China Neutropenia Biologic Drug Treatment Revenue Share by Application (2021-2032) Figure 47. Asia Neutropenia Biologic Drug Treatment Revenue YoY Growth (2021-2032) & (US$ Million) Figure 48. Asia Neutropenia Biologic Drug Treatment Revenue Share by Type (2021-2032) Figure 49. Asia Neutropenia Biologic Drug Treatment Revenue Share by Application (2021-2032) Figure 50. Asia Neutropenia Biologic Drug Treatment Revenue Share by Region (2021-2032) Figure 51. Japan Neutropenia Biologic Drug Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. South Korea Neutropenia Biologic Drug Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. India Neutropenia Biologic Drug Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Australia Neutropenia Biologic Drug Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. Taiwan Neutropenia Biologic Drug Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. Southeast Asia Neutropenia Biologic Drug Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 57. SAMEA Neutropenia Biologic Drug Treatment Revenue YoY Growth (2021-2032) & (US$ Million) Figure 58. SAMEA Neutropenia Biologic Drug Treatment Revenue Share by Type (2021-2032) Figure 59. SAMEA Neutropenia Biologic Drug Treatment Revenue Share by Application (2021-2032) Figure 60. SAMEA Neutropenia Biologic Drug Treatment Revenue Share by Country (2021-2032) Figure 61. Brazil Neutropenia Biologic Drug Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Argentina Neutropenia Biologic Drug Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Chile Neutropenia Biologic Drug Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Colombia Neutropenia Biologic Drug Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Peru Neutropenia Biologic Drug Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Saudi Arabia Neutropenia Biologic Drug Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Israel Neutropenia Biologic Drug Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. UAE Neutropenia Biologic Drug Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Turkey Neutropenia Biologic Drug Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Iran Neutropenia Biologic Drug Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Egypt Neutropenia Biologic Drug Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 72. Years Considered Figure 73. Research Process Figure 74. Key Executives Interviewed

Scope & coverage.

Types
  • Filgrastim
  • Lenograstim
  • Pegfilgrastim
  • Sargramostim
  • Lipegfilgrastim
Applications
  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies
Companies covered
  • Kyowa Kirin
  • Teva Pharmaceutical Industries Ltd.
  • Sanofi
  • Novartis
  • Pfizer
  • Baxter International
  • Amgen
  • Partner Therapeutics
  • Myelo Therapeutics GmbH
  • Enzychem Lifesciences Corporation
  • Dong-A ST Co.,Ltd.
  • CVS Health
  • Cellerant Therapeutics

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Neutropenia Biologic Drug Treatment Market by Type
  3. 1.2.1 Global Neutropenia Biologic Drug Treatment Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Filgrastim
  5. 1.2.3 Lenograstim
  6. 1.2.4 Pegfilgrastim
  7. 1.2.5 Sargramostim
  8. 1.2.6 Lipegfilgrastim
  9. 1.3 Neutropenia Biologic Drug Treatment Market by Application
  10. 1.3.1 Global Neutropenia Biologic Drug Treatment Market Size by Application, 2021 VS 2025 VS 2032
  11. 1.3.2 Hospital Pharmacies
  12. 1.3.3 Online Pharmacies
  13. 1.3.4 Retail Pharmacies
  14. 1.4 Assumptions and Limitations
  15. 1.5 Study Goals and Objectives
2 Neutropenia Biologic Drug Treatment Market Dynamics
  1. 2.1 Neutropenia Biologic Drug Treatment Industry Trends
  2. 2.2 Neutropenia Biologic Drug Treatment Industry Drivers
  3. 2.3 Neutropenia Biologic Drug Treatment Industry Opportunities and Challenges
  4. 2.4 Neutropenia Biologic Drug Treatment Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Neutropenia Biologic Drug Treatment Market Perspective (2021-2032)
  2. 3.2 Global Neutropenia Biologic Drug Treatment Growth Trends by Region
  3. 3.2.1 Global Neutropenia Biologic Drug Treatment Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Neutropenia Biologic Drug Treatment Market Size by Region (2021-2026)
  5. 3.2.3 Global Neutropenia Biologic Drug Treatment Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Neutropenia Biologic Drug Treatment Revenue by Players
  2. 4.1.1 Global Neutropenia Biologic Drug Treatment Revenue by Players (2021-2026)
  3. 4.1.2 Global Neutropenia Biologic Drug Treatment Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Neutropenia Biologic Drug Treatment Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Neutropenia Biologic Drug Treatment Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Neutropenia Biologic Drug Treatment Key Players Headquarters & Area Served
  7. 4.4 Global Neutropenia Biologic Drug Treatment Players, Product Type & Application
  8. 4.5 Global Neutropenia Biologic Drug Treatment Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Neutropenia Biologic Drug Treatment Market CR5 and HHI
  11. 4.6.3 2025 Neutropenia Biologic Drug Treatment Tier 1, Tier 2, and Tier 3
5 Neutropenia Biologic Drug Treatment Market Size by Type
  1. 5.1 Global Neutropenia Biologic Drug Treatment Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Neutropenia Biologic Drug Treatment Revenue by Type (2021-2032)
  3. 5.3 Global Neutropenia Biologic Drug Treatment Revenue Market Share by Type (2021-2032)
6 Neutropenia Biologic Drug Treatment Market Size by Application
  1. 6.1 Global Neutropenia Biologic Drug Treatment Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Neutropenia Biologic Drug Treatment Revenue by Application (2021-2032)
  3. 6.3 Global Neutropenia Biologic Drug Treatment Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Kyowa Kirin
  2. 7.1.1 Kyowa Kirin Company Information
  3. 7.1.2 Kyowa Kirin Business Overview
  4. 7.1.3 Kyowa Kirin Neutropenia Biologic Drug Treatment Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Kyowa Kirin Neutropenia Biologic Drug Treatment Product Portfolio
  6. 7.1.5 Kyowa Kirin Recent Developments
  7. 7.2 Teva Pharmaceutical Industries Ltd.
  8. 7.2.1 Teva Pharmaceutical Industries Ltd. Company Information
  9. 7.2.2 Teva Pharmaceutical Industries Ltd. Business Overview
  10. 7.2.3 Teva Pharmaceutical Industries Ltd. Neutropenia Biologic Drug Treatment Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Teva Pharmaceutical Industries Ltd. Neutropenia Biologic Drug Treatment Product Portfolio
  12. 7.2.5 Teva Pharmaceutical Industries Ltd. Recent Developments
  13. 7.3 Sanofi
  14. 7.3.1 Sanofi Company Information
  15. 7.3.2 Sanofi Business Overview
  16. 7.3.3 Sanofi Neutropenia Biologic Drug Treatment Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Sanofi Neutropenia Biologic Drug Treatment Product Portfolio
  18. 7.3.5 Sanofi Recent Developments
  19. 7.4 Novartis
  20. 7.4.1 Novartis Company Information
  21. 7.4.2 Novartis Business Overview
  22. 7.4.3 Novartis Neutropenia Biologic Drug Treatment Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Novartis Neutropenia Biologic Drug Treatment Product Portfolio
  24. 7.4.5 Novartis Recent Developments
  25. 7.5 Pfizer
  26. 7.5.1 Pfizer Company Information
  27. 7.5.2 Pfizer Business Overview
  28. 7.5.3 Pfizer Neutropenia Biologic Drug Treatment Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Pfizer Neutropenia Biologic Drug Treatment Product Portfolio
  30. 7.5.5 Pfizer Recent Developments
  31. 7.6 Baxter International
  32. 7.6.1 Baxter International Company Information
  33. 7.6.2 Baxter International Business Overview
  34. 7.6.3 Baxter International Neutropenia Biologic Drug Treatment Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Baxter International Neutropenia Biologic Drug Treatment Product Portfolio
  36. 7.6.5 Baxter International Recent Developments
  37. 7.7 Amgen
  38. 7.7.1 Amgen Company Information
  39. 7.7.2 Amgen Business Overview
  40. 7.7.3 Amgen Neutropenia Biologic Drug Treatment Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Amgen Neutropenia Biologic Drug Treatment Product Portfolio
  42. 7.7.5 Amgen Recent Developments
  43. 7.8 Partner Therapeutics
  44. 7.8.1 Partner Therapeutics Company Information
  45. 7.8.2 Partner Therapeutics Business Overview
  46. 7.8.3 Partner Therapeutics Neutropenia Biologic Drug Treatment Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Partner Therapeutics Neutropenia Biologic Drug Treatment Product Portfolio
  48. 7.8.5 Partner Therapeutics Recent Developments
  49. 7.9 Myelo Therapeutics GmbH
  50. 7.9.1 Myelo Therapeutics GmbH Company Information
  51. 7.9.2 Myelo Therapeutics GmbH Business Overview
  52. 7.9.3 Myelo Therapeutics GmbH Neutropenia Biologic Drug Treatment Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Myelo Therapeutics GmbH Neutropenia Biologic Drug Treatment Product Portfolio
  54. 7.9.5 Myelo Therapeutics GmbH Recent Developments
  55. 7.10 Enzychem Lifesciences Corporation
  56. 7.10.1 Enzychem Lifesciences Corporation Company Information
  57. 7.10.2 Enzychem Lifesciences Corporation Business Overview
  58. 7.10.3 Enzychem Lifesciences Corporation Neutropenia Biologic Drug Treatment Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Enzychem Lifesciences Corporation Neutropenia Biologic Drug Treatment Product Portfolio
  60. 7.10.5 Enzychem Lifesciences Corporation Recent Developments
  61. 7.11 Dong-A ST Co.,Ltd.
  62. 7.11.1 Dong-A ST Co.,Ltd. Company Information
  63. 7.11.2 Dong-A ST Co.,Ltd. Business Overview
  64. 7.11.3 Dong-A ST Co.,Ltd. Neutropenia Biologic Drug Treatment Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Dong-A ST Co.,Ltd. Neutropenia Biologic Drug Treatment Product Portfolio
  66. 7.11.5 Dong-A ST Co.,Ltd. Recent Developments
  67. 7.12 CVS Health
  68. 7.12.1 CVS Health Company Information
  69. 7.12.2 CVS Health Business Overview
  70. 7.12.3 CVS Health Neutropenia Biologic Drug Treatment Revenue and Gross Margin (2021-2026)
  71. 7.12.4 CVS Health Neutropenia Biologic Drug Treatment Product Portfolio
  72. 7.12.5 CVS Health Recent Developments
  73. 7.13 Cellerant Therapeutics
  74. 7.13.1 Cellerant Therapeutics Company Information
  75. 7.13.2 Cellerant Therapeutics Business Overview
  76. 7.13.3 Cellerant Therapeutics Neutropenia Biologic Drug Treatment Revenue and Gross Margin (2021-2026)
  77. 7.13.4 Cellerant Therapeutics Neutropenia Biologic Drug Treatment Product Portfolio
  78. 7.13.5 Cellerant Therapeutics Recent Developments
8 North America
  1. 8.1 North America Neutropenia Biologic Drug Treatment Revenue (2021-2032)
  2. 8.2 North America Neutropenia Biologic Drug Treatment Revenue by Type (2021-2032)
  3. 8.2.1 North America Neutropenia Biologic Drug Treatment Revenue by Type (2021-2026)
  4. 8.2.2 North America Neutropenia Biologic Drug Treatment Revenue by Type (2027-2032)
  5. 8.3 North America Neutropenia Biologic Drug Treatment Revenue Share by Type (2021-2032)
  6. 8.4 North America Neutropenia Biologic Drug Treatment Revenue by Application (2021-2032)
  7. 8.4.1 North America Neutropenia Biologic Drug Treatment Revenue by Application (2021-2026)
  8. 8.4.2 North America Neutropenia Biologic Drug Treatment Revenue by Application (2027-2032)
  9. 8.5 North America Neutropenia Biologic Drug Treatment Revenue Share by Application (2021-2032)
  10. 8.6 North America Neutropenia Biologic Drug Treatment Revenue by Country
  11. 8.6.1 North America Neutropenia Biologic Drug Treatment Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Neutropenia Biologic Drug Treatment Revenue by Country (2021-2026)
  13. 8.6.3 North America Neutropenia Biologic Drug Treatment Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
9 Europe
  1. 9.1 Europe Neutropenia Biologic Drug Treatment Revenue (2021-2032)
  2. 9.2 Europe Neutropenia Biologic Drug Treatment Revenue by Type (2021-2032)
  3. 9.2.1 Europe Neutropenia Biologic Drug Treatment Revenue by Type (2021-2026)
  4. 9.2.2 Europe Neutropenia Biologic Drug Treatment Revenue by Type (2027-2032)
  5. 9.3 Europe Neutropenia Biologic Drug Treatment Revenue Share by Type (2021-2032)
  6. 9.4 Europe Neutropenia Biologic Drug Treatment Revenue by Application (2021-2032)
  7. 9.4.1 Europe Neutropenia Biologic Drug Treatment Revenue by Application (2021-2026)
  8. 9.4.2 Europe Neutropenia Biologic Drug Treatment Revenue by Application (2027-2032)
  9. 9.5 Europe Neutropenia Biologic Drug Treatment Revenue Share by Application (2021-2032)
  10. 9.6 Europe Neutropenia Biologic Drug Treatment Revenue by Country
  11. 9.6.1 Europe Neutropenia Biologic Drug Treatment Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Neutropenia Biologic Drug Treatment Revenue by Country (2021-2026)
  13. 9.6.3 Europe Neutropenia Biologic Drug Treatment Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Netherlands
  19. 9.6.9 Nordic Countries
10 China
  1. 10.1 China Neutropenia Biologic Drug Treatment Revenue (2021-2032)
  2. 10.2 China Neutropenia Biologic Drug Treatment Revenue by Type (2021-2032)
  3. 10.2.1 China Neutropenia Biologic Drug Treatment Revenue by Type (2021-2026)
  4. 10.2.2 China Neutropenia Biologic Drug Treatment Revenue by Type (2027-2032)
  5. 10.3 China Neutropenia Biologic Drug Treatment Revenue Share by Type (2021-2032)
  6. 10.4 China Neutropenia Biologic Drug Treatment Revenue by Application (2021-2032)
  7. 10.4.1 China Neutropenia Biologic Drug Treatment Revenue by Application (2021-2026)
  8. 10.4.2 China Neutropenia Biologic Drug Treatment Revenue by Application (2027-2032)
  9. 10.5 China Neutropenia Biologic Drug Treatment Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Neutropenia Biologic Drug Treatment Revenue (2021-2032)
  2. 11.2 Asia Neutropenia Biologic Drug Treatment Revenue by Type (2021-2032)
  3. 11.2.1 Asia Neutropenia Biologic Drug Treatment Revenue by Type (2021-2026)
  4. 11.2.2 Asia Neutropenia Biologic Drug Treatment Revenue by Type (2027-2032)
  5. 11.3 Asia Neutropenia Biologic Drug Treatment Revenue Share by Type (2021-2032)
  6. 11.4 Asia Neutropenia Biologic Drug Treatment Revenue by Application (2021-2032)
  7. 11.4.1 Asia Neutropenia Biologic Drug Treatment Revenue by Application (2021-2026)
  8. 11.4.2 Asia Neutropenia Biologic Drug Treatment Revenue by Application (2027-2032)
  9. 11.5 Asia Neutropenia Biologic Drug Treatment Revenue Share by Application (2021-2032)
  10. 11.6 Asia Neutropenia Biologic Drug Treatment Revenue by Country
  11. 11.6.1 Asia Neutropenia Biologic Drug Treatment Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Neutropenia Biologic Drug Treatment Revenue by Country (2021-2026)
  13. 11.6.3 Asia Neutropenia Biologic Drug Treatment Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Neutropenia Biologic Drug Treatment Revenue (2021-2032)
  2. 12.2 SAMEA Neutropenia Biologic Drug Treatment Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Neutropenia Biologic Drug Treatment Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Neutropenia Biologic Drug Treatment Revenue by Type (2027-2032)
  5. 12.3 SAMEA Neutropenia Biologic Drug Treatment Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Neutropenia Biologic Drug Treatment Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Neutropenia Biologic Drug Treatment Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Neutropenia Biologic Drug Treatment Revenue by Application (2027-2032)
  9. 12.5 SAMEA Neutropenia Biologic Drug Treatment Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Neutropenia Biologic Drug Treatment Revenue by Country
  11. 12.6.1 SAMEA Neutropenia Biologic Drug Treatment Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Neutropenia Biologic Drug Treatment Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Neutropenia Biologic Drug Treatment Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst